Skip to main content
Erschienen in: Der Urologe 11/2015

01.11.2015 | Übersichten

Interdisziplinäre und individualisierte Therapie des Prostatakarzinoms

Internationales Prostatakrebssymposium Bonn 2013 – Herausforderungen und Ziele

verfasst von: M. Schwardt, J. Debus, G. Feick, B. Hadaschik, M. Hohenfellner, R. Schüle, J.-P. Zacharias, Prof. Dr. S.E. Combs

Erschienen in: Die Urologie | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die multimodale Behandlung des Prostatakarzinoms basiert heute auf einem spezifischen Staging mit Bildgebung, klinischen Parametern, Tumormarkern sowie histopathologischer Charakterisierung. Die stadiengerechte Therapie kann initial entweder eine „Wait-and-see-Strategie“, eine aktive Überwachung, eine chirurgische Intervention, eine Strahlentherapie oder eine Hormontherapie umfassen. In einigen klinischen Szenarien kann auch eine Kombination dieser Behandlungsformen sinnvoll sein. Neben tumorbedingten Entscheidungskriterien beeinflussen auch patientenspezifische Faktoren und Präferenzen die Wahl der Therapieform. Im Rahmen des internationalen Meetings „Challenges and Chances in Prostate Cancer Research“ der Deutschen Krebshilfe wurden von führenden Urologen, Strahlentherapeuten, Epidemiologen und Vertretern andere Fachdisziplinen State-of-the-art-Behandlungskonzepte vorgestellt und diskutiert, sowie innovative Studienkonzepte und translationale Forschungsprojekte zur Diskussion gestellt.
Literatur
1.
Zurück zum Zitat Schroder FH, Hugosson J, Roobol MJ et al (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11):981–990CrossRefPubMed Schroder FH, Hugosson J, Roobol MJ et al (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11):981–990CrossRefPubMed
2.
Zurück zum Zitat Brett AS, Ablin RJ (2011) Prostate-cancer screening – what the U.S. Preventive Services Task Force left out. N Engl J Med 365(21):1949–1951CrossRefPubMed Brett AS, Ablin RJ (2011) Prostate-cancer screening – what the U.S. Preventive Services Task Force left out. N Engl J Med 365(21):1949–1951CrossRefPubMed
3.
Zurück zum Zitat McNaughton-Collins MF, Barry MJ (2011) One man at a time – resolving the PSA controversy. N Engl J Med 365(21):1951–1953CrossRefPubMed McNaughton-Collins MF, Barry MJ (2011) One man at a time – resolving the PSA controversy. N Engl J Med 365(21):1951–1953CrossRefPubMed
4.
Zurück zum Zitat Schroder FH (2011) Stratifying risk – the U.S. Preventive Services Task Force and prostate-cancer screening. N Engl J Med 365(21):1953–1955CrossRefPubMed Schroder FH (2011) Stratifying risk – the U.S. Preventive Services Task Force and prostate-cancer screening. N Engl J Med 365(21):1953–1955CrossRefPubMed
5.
Zurück zum Zitat Budaus L, Spethmann J, Isbarn H et al (2011) Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int 108(8):1256–1261CrossRefPubMed Budaus L, Spethmann J, Isbarn H et al (2011) Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int 108(8):1256–1261CrossRefPubMed
6.
Zurück zum Zitat Djulbegovic M, Beyth RJ, Neuberger MM et al (2010) Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 341:4543CrossRef Djulbegovic M, Beyth RJ, Neuberger MM et al (2010) Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 341:4543CrossRef
7.
Zurück zum Zitat Eichler K, Hempel S, Wilby J et al (2006) Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 175(5):1605–1612CrossRefPubMed Eichler K, Hempel S, Wilby J et al (2006) Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 175(5):1605–1612CrossRefPubMed
8.
Zurück zum Zitat Roethke MC, Kuru TH, Afshar-Oromieh A et al (2013) Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results. Eur Urol 64(5):862–864CrossRefPubMed Roethke MC, Kuru TH, Afshar-Oromieh A et al (2013) Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results. Eur Urol 64(5):862–864CrossRefPubMed
9.
Zurück zum Zitat Afshar-Oromieh A, Zechmann CM, Malcher A et al (2013) Comparison of PET imaging with a Ga-labelled PSMA ligand and F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 40(10):1629–1630CrossRefPubMed Afshar-Oromieh A, Zechmann CM, Malcher A et al (2013) Comparison of PET imaging with a Ga-labelled PSMA ligand and F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 40(10):1629–1630CrossRefPubMed
10.
Zurück zum Zitat Boyd LK, Mao X, Lu YJ (2012) The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol 9(11):652–664CrossRefPubMed Boyd LK, Mao X, Lu YJ (2012) The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol 9(11):652–664CrossRefPubMed
11.
Zurück zum Zitat Weischenfeldt J, Simon R, Feuerbach L et al (2013) Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23(2):159–170CrossRefPubMed Weischenfeldt J, Simon R, Feuerbach L et al (2013) Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23(2):159–170CrossRefPubMed
12.
Zurück zum Zitat Cuevas R, Korzeniewski N, Tolstov Y et al (2013) FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57. Cancer Res 73(4):1400–1410CrossRefPubMed Cuevas R, Korzeniewski N, Tolstov Y et al (2013) FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57. Cancer Res 73(4):1400–1410CrossRefPubMed
13.
Zurück zum Zitat Korzeniewski N, Hohenfellner M, Duensing S (2012) CAND1 promotes PLK4-mediated centriole overduplication and is frequently disrupted in prostate cancer. Neoplasia 14(9):799–806PubMedCentralCrossRefPubMed Korzeniewski N, Hohenfellner M, Duensing S (2012) CAND1 promotes PLK4-mediated centriole overduplication and is frequently disrupted in prostate cancer. Neoplasia 14(9):799–806PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Prensner JR, Iyer MK, Balbin OA et al (2011) Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 29(8):742–749PubMedCentralCrossRefPubMed Prensner JR, Iyer MK, Balbin OA et al (2011) Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 29(8):742–749PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Markert EK, Mizuno H, Vazquez A, Levine AJ (2011) Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA 108(52):21276–21281PubMedCentralCrossRefPubMed Markert EK, Mizuno H, Vazquez A, Levine AJ (2011) Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA 108(52):21276–21281PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Kannan K, Wang L, Wang J et al (2011) Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci USA 108(22):9172–9177PubMedCentralCrossRefPubMed Kannan K, Wang L, Wang J et al (2011) Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci USA 108(22):9172–9177PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Zoubeidi A, Chi K, Gleave M (2010) Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 16(4):1088–1093PubMedCentralCrossRefPubMed Zoubeidi A, Chi K, Gleave M (2010) Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 16(4):1088–1093PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Metzger E, Imhof A, Patel D et al (2010) Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 464(7289):792–796CrossRefPubMed Metzger E, Imhof A, Patel D et al (2010) Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 464(7289):792–796CrossRefPubMed
19.
Zurück zum Zitat Huber J, Herpel E, Jakobi H et al (2012) Two decades‘ experience with a prospective biobank for urologic oncology: research, clinical care, and the patients‘ view. Urol Oncol 33(2):97–110 Huber J, Herpel E, Jakobi H et al (2012) Two decades‘ experience with a prospective biobank for urologic oncology: research, clinical care, and the patients‘ view. Urol Oncol 33(2):97–110
20.
Zurück zum Zitat Hatiboglu G, Pinkawa M, Vallee JP et al (2012) Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int 110(11 Pt B):647–652CrossRef Hatiboglu G, Pinkawa M, Vallee JP et al (2012) Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int 110(11 Pt B):647–652CrossRef
21.
Zurück zum Zitat Zietman AL, DeSilvio ML, Slater JD et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10):1233–1239CrossRefPubMed Zietman AL, DeSilvio ML, Slater JD et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10):1233–1239CrossRefPubMed
22.
Zurück zum Zitat Minniti D, Chiado Piat S, Di Novi C (2011) Robot-assisted versus open radical prostatectomy: an evidence-based comparison. Technol Health Care 19(5):331–339PubMed Minniti D, Chiado Piat S, Di Novi C (2011) Robot-assisted versus open radical prostatectomy: an evidence-based comparison. Technol Health Care 19(5):331–339PubMed
23.
Zurück zum Zitat Barry MJ, Gallagher PM, Skinner JS, Fowler FJ Jr (2012) Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men. J Clin Oncol 30(5):513–518PubMedCentralCrossRefPubMed Barry MJ, Gallagher PM, Skinner JS, Fowler FJ Jr (2012) Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men. J Clin Oncol 30(5):513–518PubMedCentralCrossRefPubMed
24.
Zurück zum Zitat Asimakopoulos AD, Pereira Fraga CT, Annino F et al (2011) Randomized comparison between laparoscopic and robot-assisted nerve-sparing radical prostatectomy. J Sex Med 8(5):1503–1512CrossRefPubMed Asimakopoulos AD, Pereira Fraga CT, Annino F et al (2011) Randomized comparison between laparoscopic and robot-assisted nerve-sparing radical prostatectomy. J Sex Med 8(5):1503–1512CrossRefPubMed
25.
Zurück zum Zitat Montague DK (2005) Penile prosthesis implantation for end-stage erectile dysfunction after radical prostatectomy. Rev Urol 7(Suppl 2):51–57 Montague DK (2005) Penile prosthesis implantation for end-stage erectile dysfunction after radical prostatectomy. Rev Urol 7(Suppl 2):51–57
26.
Zurück zum Zitat Zelefsky MJ, Eastham JA, Cronin AM et al (2010) Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28(9):1508–1513PubMedCentralCrossRefPubMed Zelefsky MJ, Eastham JA, Cronin AM et al (2010) Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28(9):1508–1513PubMedCentralCrossRefPubMed
Metadaten
Titel
Interdisziplinäre und individualisierte Therapie des Prostatakarzinoms
Internationales Prostatakrebssymposium Bonn 2013 – Herausforderungen und Ziele
verfasst von
M. Schwardt
J. Debus
G. Feick
B. Hadaschik
M. Hohenfellner
R. Schüle
J.-P. Zacharias
Prof. Dr. S.E. Combs
Publikationsdatum
01.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Urologie / Ausgabe 11/2015
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-014-3580-7

Weitere Artikel der Ausgabe 11/2015

Der Urologe 11/2015 Zur Ausgabe

Geschichte der Urologie

„Zukunft braucht Erinnerung“*

Neu im Fachgebiet Urologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.